<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341454</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012305</org_study_id>
    <nct_id>NCT04341454</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis</brief_title>
  <official_title>A Multi-Center, Double-blind, Randomized, Placebo-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to confirm the efficacy of DWP14012 X mg QD, DWP14012 Y mg BID
      compared to placebo in patients with Acute or Chronic Gastritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a multi-center, randomized, double-blind, placebo-controlled,
      parallel-group, phase 3 study to assess the efficacy and safety of oral administration of
      DWP14012 X mg QD, Y mg BID and placebo for 2 weeks in patients with acute and chronic
      gastritis.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rate of gastric mucosal erosion</measure>
    <time_frame>at 2 weeks after the IP administration</time_frame>
    <description>Improvement rate (%) = (Number of effective cases(change of ≥ 50% in erosion score) / Number of target cases) x 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate of gastric mucosal erosion</measure>
    <time_frame>at 2 weeks after the IP administration</time_frame>
    <description>Cure rate (%) = (Number of healed cases(0 erosions) / Number of target cases) x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure rate of gastric mucosal edema</measure>
    <time_frame>at 2 weeks after the IP administration</time_frame>
    <description>Cure rate (%) = (Number of healed cases(change of 2 to 1 in edema score) / Number of target cases) x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of gastric mucosal erythema</measure>
    <time_frame>at 2 weeks after the IP administration</time_frame>
    <description>Improvement rate (%) = (Number of effective cases(change of ≥ 50% in erythema score) / Number of target cases) x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of gastric mucosal bleeding</measure>
    <time_frame>at 2 weeks after the IP administration</time_frame>
    <description>Improvement rate (%) = (Number of effective cases(change of ≥ 50% in bleeding score) / Number of target cases) x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of subjective symptoms</measure>
    <time_frame>at 2 weeks after the IP administration</time_frame>
    <description>Improvement rate (%) = (Number of effective cases(change of ≥ 50% in subjective symptom score) / Number of target cases) x 100</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">327</enrollment>
  <condition>Acute Gastritis</condition>
  <condition>Chronic Gastritis</condition>
  <arm_group>
    <arm_group_label>DWP14012 X mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo
Evening: 1 tablet of DWP14012 Y mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP14012 Y mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg
Evening: 1 tablet of DWP14012 Y mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo
Evening: 1 tablet of DWP14012 Y mg placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 X mg</intervention_name>
    <description>DWP14012 X mg, tablet, orally, once daily for 2 weeks</description>
    <arm_group_label>DWP14012 X mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 X mg placebo</intervention_name>
    <description>DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks</description>
    <arm_group_label>DWP14012 Y mg BID</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Y mg</intervention_name>
    <description>DWP14012 Y mg, tablet, orally, twice daily for 2 weeks</description>
    <arm_group_label>DWP14012 Y mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Y mg placebo</intervention_name>
    <description>DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks</description>
    <arm_group_label>DWP14012 X mg QD</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 19 and 75 years old based on the date of written agreement

          -  Those who are diagnosed with acute or chronic gastritis with at least one erosion
             observed on upper gastrointestinal endoscopy

          -  Those who had experienced one or more subjective symptoms of gastritis

        Exclusion Criteria:

          -  Those who have had surgery to reduce gastric acid secretion, or gastric or esophageal
             surgery

          -  Those with history of clinically significant hepatic, renal, neurologic, pulmonary,
             endocrine, hematologic, cardiovascular or genitourinary disease that could affect the
             study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

